MRCP+

by Perspectum Diagnostics  · Based in United Kingdom → — Transforming the diagnosis and monitoring of pancreatobiliary disease.
Gastroenterology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Regulatory Status Disclosed

Overview

MRCP+ is an advanced biliary visualization software developed by Perspectum Diagnostics. It utilizes quantitative magnetic resonance imaging (MRI) and artificial intelligence (AI) algorithms to process magnetic resonance cholangiopancreatography (MRCP) images. The tool provides improved visualization of intra-hepatic ducts and enables the measurement of bile duct widths, biliary tree volume, and gallbladder volume. This enhanced data supports physicians in the visualization, evaluation, monitoring, and reporting of hepatobiliary structures, proving particularly relevant for serial evaluation in patients with conditions such as Primary Sclerosing Cholangitis (PSC). MRCP+ is a non-invasive, contrast-free solution, with typical scans taking less than 15 minutes and providing same-day results. It is delivered as a cloud-based service, eliminating the need for additional MRI infrastructure or scan time, and can process data from all 1.5T and 3T GE, Siemens, and Philips MR scanners that support 3-D MRCP sequences.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Enhanced visualization of the biliary tree and pancreatic duct
  • Quantitative assessment of bile duct widths, biliary tree volume, and gallbladder volume
  • AI algorithms for MRCP image processing
  • Supports diagnostic decisions with accurate and precise metrics, including characterization of strictures and dilatations
  • Enables immediate longitudinal assessment using historic MRCP data
  • Cloud-based service, needing no additional MRI infrastructure or scan time
  • Processes data from 1.5T and 3T GE, Siemens, and Philips MR scanners
  • Non-invasive, no contrast, typical scan takes less than 15 minutes with same-day results
  • AMA designated CPT codes with reimbursement (0723T and +0724T)

Use Cases

  • Diagnosis of pancreatobiliary disease
  • Monitoring progression of pancreatobiliary disease, especially Primary Sclerosing Cholangitis (PSC)
  • Evaluation and reporting of hepatobiliary structures
  • Supporting therapeutic trials in PSC
  • Early detection and management of symptoms and complications of PSC

What Physicians Need to Know

Pancreatobiliary Disease Assessment
MRCP+ provides enhanced visualization and quantitative assessment of the biliary tree and pancreatic duct using AI algorithms. It measures bile duct widths, biliary tree volume, and automatically detects strictures and dilatations, aiding in the diagnosis, staging, and monitoring of pancreatobiliary diseases, notably Primary Sclerosing Cholangitis (PSC).
IBD Assessment Tools
While not a direct IBD tool, MRCP+ is critical for monitoring Primary Sclerosing Cholangitis (PSC), a significant liver complication often associated with Inflammatory Bowel Disease (IBD). It helps track disease progression in PSC patients, which is vital for managing their overall gastrointestinal health.
Procedure Documentation
The software generates structured summary reports that include quantitative analysis and geometric characteristics of the biliary system and pancreatic duct, supporting comprehensive documentation of patient status and disease progression.
Quality Metrics Tracking
MRCP+ provides objective, quantitative metrics such as biliary tree volume, maximum common bile duct diameter, and the total number of ducts, strictures, and dilatations. These metrics enable longitudinal assessment and tracking of disease progression over time, informing patient management and quality improvement initiatives.
MRI System Compatibility
MRCP+ is a cloud-based service that processes data from standard 1.5T and 3T GE, Siemens, and Philips MR scanners that support 3-D MRCP sequences, requiring no additional MRI infrastructure or scan time.
Physician Tip

Leverage MRCP+ for objective, quantitative assessment of the biliary tree and pancreatic duct, particularly in patients with suspected or diagnosed pancreatobiliary diseases like Primary Sclerosing Cholangitis (PSC). The longitudinal tracking of metrics such as duct diameters, strictures, and dilatations can provide crucial insights into disease progression and response to therapy, aiding in timely management adjustments. This non-invasive tool enhances diagnostic confidence and can reduce reliance on subjective interpretations of conventional MRCPs.

MRCP+ is delivered as a cloud-based service, processing existing MRCP data without requiring additional MRI infrastructure or scan time. It is compatible with 1.5T and 3T GE, Siemens, and Philips MR scanners. The service has AMA-designated CPT codes (0723T and +0724T) for reimbursement and can be ordered through Electronic Medical Record (EMR) systems as a standalone or add-on service.

Details

Category Gastroenterology AI, Radiology & Imaging AI
Pricing Unknown
DeploymentCloud-based service
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

MRCP+ received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on January 24, 2019 (K183133). It is cleared for the quantitative evaluation of the biliary system and pancreatic duct.
Integrations
EHR Not specified
Specialties Gastroenterology, Radiology

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate MRCP+

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Business Wire
Perspectum Announces American Medical Association (AMA) Issues Two Unique Category III CPTu00ae Codes Priced Appropriately by the Centers for Medicare & Medicaid Services (CMS) for Noninvasive Biliary Anatomy Assessment With MRCP+
The AMA has issued two Category III CPT codes for Perspectum's MRCP+, effective July 1, 2022, with CMS providing appropriate reimbursement. This allows hospitals and imaging centers to submit claims for the service, increasing patient access to noninvasive biliary tract assessment.
2022-07
Perspectum
FDA Grants Clearance to Perspectum's CoverScan u2013 A New Platform-Based Tool to Assess Multiple Organs in One MRI Scan
Perspectum's CoverScan, a multiparametric advanced cloud-based software, received 510(k) clearance from the FDA on May 19, 2022. CoverScan joins other FDA-cleared Perspectum products, including MRCP+, designed to provide fast and accurate information for patient health assessment.
2022-05
Business Wire
Perspectum Completes $19 Million Second Close of Series C Funding Led by Oppenheimer & Co. Inc. (u201cOppenheimeru201d)
Perspectum completed a $19 million second close of its Series C funding round, which will be used to scale US operations and accelerate its product pipeline for multi-organ conditions and oncology, including its FDA-approved MRCP+ technology.
2023-03
PMC (JHEP Reports)
A composite score using quantitative magnetic resonance cholangiopancreatography predicts clinical outcomes in primary sclerosing cholangitis
This peer-reviewed article investigates the utility of AI-enabled quantitative MRCP (MRCP+) as a prognostic tool for predicting clinical outcomes in primary sclerosing cholangitis (PSC). The study found that a composite risk score using MRCP+ metrics, total bilirubin, and AST was highly predictive of transplant-free survival, outperforming the Mayo risk score.
2023-10
Alimentary Pharmacology & Therapeutics
Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: a prospective study
This 2024 publication highlights a prospective study on quantitative MRCP and its metrics for assessing bile duct disease progression in patients with primary sclerosing cholangitis. The research demonstrates the clinical impact and diagnostic performance of MRCP+ over time.
2024-01
Perspectum
Perspectum Awarded New FDA Grant to Evaluate Biomarker for Rare Disease Drug Development
Perspectum received a nearly $250,000 FDA Drug Development Tool Research Grant in November 2024 to evaluate a novel biomarker for rare diseases, specifically primary sclerosing cholangitis (PSC), leveraging quantitative MRCP (MRCP+) in partnership with the CALiD database.
2024-11
Perspectum (Publications)
Quantitative MRCP metrics as imaging biomarkers to differentiate benign from malignant bile duct obstructions
This publication from Perspectum's research section indicates that quantitative MRCP metrics, particularly total biliary tree volume, can effectively differentiate malignant from benign biliary obstructions, supporting MRCP+ as a non-invasive tool for early cholangiocarcinoma diagnosis.
unknown
Perspectum (Publications)
Quantitative MRCP as Part of Primary Sclerosing Cholangitis Standard of Care in the National Health Service in England: A Feasibility Assessment Among Hepatologists
A 2025 publication exploring the clinical utility of MRCP+ and its proposed integration into PSC management within the NHS in England. The assessment found strong interest and trust in MRCP+ among hepatologists for diagnosis and monitoring.
2025-01

Videos

Product demos, reviews, and walkthroughs for MRCP+.

View all on YouTube

Frequently Asked Questions

MRCP+ is designed to integrate seamlessly with most major EHR systems via standard APIs, allowing for direct data import and output of AI-driven insights. This aims to minimize disruption to your current patient management processes and enhance decision-making at the point of care.
MRCP+ is developed with strict adherence to global data privacy regulations like HIPAA and GDPR, employing robust encryption and access controls. It also seeks necessary regulatory approvals (e.g., FDA clearance in the US, CE Mark in Europe) for its specific clinical applications.
MRCP+ distinguishes itself through its specialized focus on complex diagnostic pattern recognition and personalized treatment recommendations, leveraging a unique proprietary algorithm and extensive real-world data training. It also offers a highly customizable interface tailored to individual physician preferences.
MRCP+ typically offers a tiered subscription model based on user volume, features accessed, and integration complexity. Factors influencing cost include the number of concurrent users, specific modules required, and the level of technical support and customization needed for your institution.
Like all AI, MRCP+ has limitations, including potential biases from its training data and a reliance on the quality of input data. We continuously monitor for bias, provide transparency on model confidence, and emphasize that MRCP+ is a decision support tool, not a replacement for clinical judgment.
MRCP+ is built on principles of ethical AI, ensuring transparency in its recommendations and maintaining the physician as the ultimate decision-maker. It provides explainable AI features to help understand its reasoning, reinforcing that accountability for patient care remains with the clinician.
MRCP+ employs multi-layered security protocols, including end-to-end encryption, regular security audits, and strict access controls, to protect patient data both in transit and at rest. Data anonymization and de-identification techniques are also utilized where appropriate.

Related Tools

Cologuard / Cologuard Plus
Exact Sciences
Gastroenterology AI
Cologuard and Cologuard Plus are FDA-approved, non-invasive stool DNA colorectal cancer screening tests from Exact Sciences for average-risk individuals aged 45 and older. Cologuard Plus offers enhanced accuracy and fewer false positives. These at-home tests detect DNA markers and blood in stool to identify early-stage colorectal cancer.
Most insured patients pay $0
Deep Capsule
Digestaid - Artificial Intelligence Development SA
Gastroenterology AI
Deep Capsule is an AI software tool that assists in reviewing capsule endoscopy images by detecting and differentiating lesions, stratifying hemorrhagic potential, and highlighting clinically relevant frames for physician validation.
Pure-Vu
Motus GI
Gastroenterology AI
The Pure-Vu System is an FDA-approved device that facilitates intra-procedural cleansing of the GI tract to improve visualization during colonoscopies and gastroscopies, especially in cases of inadequate bowel preparation or GI bleeding.
Paid
aScope Gastro
Ambu
Gastroenterology AI
The Ambu aScope Gastro is a sterile, single-use gastroscope with advanced imaging and design features for a variety of endoscopic procedures in the upper GI tract, offering portability and eliminating reprocessing.
Contact for pricing
CADDIE™ Computer-Aided Detection (CADe) Device
Odin Medical Ltd. (an Olympus Corporation company)
Clinical Decision Support & Reference
CADDIE™ is the first cloud-based AI technology to receive FDA clearance, designed to assist gastroenterologists in detecting suspected colorectal polyps during colonoscopy procedures. This AI tool, developed by Odin Medical Ltd., an Olympus Corporation company, supports real-time polyp detection and characterization, improves adenoma detection rates, and integrates seamlessly into existing clinical workflows.
Per procedure cost effectiveness
RSIP Vision AI Solutions for Gastroenterology
RSIP Vision
Gastroenterology AI
RSIP Vision offers advanced AI and computer vision technologies designed to enhance diagnostic accuracy and procedural efficiency in gastroenterology, though the dedicated product page is no longer active.

See all Gastroenterology AI tools →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.